The role of interleukin-3 in classical Hodgkin's disease

Leukemia and Lymphoma

Volumn 46, Issue 3, 2005, Pages 303-311

  Aldinucci, Donatella ^a   Olivo, Karin ^a   Lorenzon, Debora ^a   Poletto, Dalisa ^a   Gloghini, Annunziata ^a   Carbone, Antonino ^a   Pinto, Antonio ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

H RS cell growth; IL 3; IL 3 receptor; T cells

Indexed keywords

APOPTOSIS INHIBITOR; CELL PROTEIN; CHEMOKINE; CYTOKINE; INTERLEUKIN 3; INTERLEUKIN 3 RECEPTOR; INTERLEUKIN 9; MESSENGER RNA; STEM CELL FACTOR;

ALPHA CHAIN; APOPTOSIS; BETA CHAIN; BONE MARROW CELL; CANCER CELL CULTURE; CELL ACTIVATION; CELL GROWTH; CELL MOTILITY; CELL STIMULATION; CELL SURVIVAL; CELL SUSPENSION; CLINICAL FEATURE; CYTOKINE PRODUCTION; FREQUENCY ANALYSIS; FROZEN SECTION; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHOMA; MOLECULAR INTERACTION; MOLECULAR SIZE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR PROMOTION;

APOPTOSIS; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; INTERLEUKIN-3; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; PARACRINE COMMUNICATION; RECEPTORS, INTERLEUKIN-3; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION;

EID: 13544271150     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400013712     Document Type: Review

References (105)

1. Anastasi J, Bitter MA, Vardiman JW. The histopathologic diagnosis and subclassification of Hodgkin's disease. Hematol Oncol Clin North Am 1989;3:187-204.
2. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol 1999;12:159-175.
3. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283-4297.
4. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997;18:156-163.
5. Pinto A, Gattei V, Zagonel V, Aldinucci D, Degan M, De Juiliis A, Rossi FM, Tassan Mazzocco F, Godeas C, Rupolo M, Poletto D, Gloghini A, Carbone A, Gruss HJ. Hodgkin's disease: a disorder of dysregulated cellular cross-talk. Biotherapy 1998;10:309-320.
6. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab Invest 1998;78:229-235.
7. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Sesuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93:2463-2470.
8. Hanamoto H, Nakayama T, Miyazato H, Takegawa S, Hieshima K, Tatsumi Y, Kanamaru A, Yoshie O. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004;164:997-1006.
9. Fischer M, Juremalm M, Olsson N, Backlin C, Sundstrom C, Nilsson K, Enblad G, Nilsson G. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer 2003;107:197-201.
10. Skinnider BF, Kapp U, Mak TW. The role of interleukin 13 in classical Hodgkin lymphoma. Leuk Lymphoma 2002;43:1203-1210.
11. Aldinucci D, Lorenzon D, Olivo K, Rapana B, Gattei V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed-Sternberg cells. Leuk Lymphoma 2004;45:1731-1739.
12. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Müller G, Foss HD, Royer HD, Stein H, Dörken B. Hodgkin/Reed-Sternberg cells induce fibroblast to secrete eotaxin, a potent chemoattractant for T-cells and eosinophils. Blood 1999;94:2065-2071.
13. Newcom SR, Ansari A, Gu L. Interleukin-4 is an autocrine growth factor secreted by the L-428 Reed-Sternberg cell. Blood 1992;79:191-197.
14. Jücker M, Abts H, Li W, Schindler R, Merz H, Gunther A, von Kalle C, Schadt M, Diamanstein T, Feller AC. Expression of interleukin 6 and interleukin 6 receptor in Hodgkin's disease. Blood 1991;77:2413-2418.
15. Merz H, Houssiau FA, Orsheschek K, Renauld JC, Fliedner A, Herin M, Noel H, Kadin M, Mueller-Hemerlink HK, Van Snick J. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large cell anaplastic lymphoma. Blood 1991;78:1311-1317.
16. Gruss HJ, Brach MA, Drexler HG, Bross KJ, Herrmann F. Interleukin-9 is expressed by primary and cultured Hodgkin and Reed-Sternberg cells. Cancer Res 1992;52:1026-1031.
17. Paietta E, Racevskis J, Stanley ER, Andreef M, Papenhausen P, Wiernik PH. Expression of the macrophage growth factor, CSF-1 and its receptor c-fms by a Hodgkin's disease-derived cell line and its variants. Cancer Res 1990;50:2049-2055.
18. Messineo C, Jamerson MH, Hunter E, Braziel R, Bagg A, Irving SG, Cossman J. Gene expression by single Reed-Sternberg cells: pathways of apotosis and activation. Blood 1998;91:2443-2451.
19. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Hessel HA, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M, Mak TW. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999;189:1939-1946.
20. Maggio E, van den Berg A, Diepstra A, Kluiver J, Visser L, Poppema S. Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues. Ann Oncol 2002;13:52-56.
21. Aldinucci D, Poletto D, Gloghini A, Nanni P, Degan M, Perin T, Ceolin P, Rossi FM, Gattei V, Carbone A, Pinto A. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol 2002;160:585-596.
22. Bagley CY, Woodcock JM, Stomski FC, Lopez AF. The structural and functional basis of cytokine receptor activation: lessons from the common beta subunit of the granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3) and IL-5. Blood 1997;89:1471-1482.
23. Miyajima A, Mui AL, Ogorochi T, Sakamaki K. Receptors for granulocyte-macrophage colony-stimulating factor, interleukin-3, and interleukin-5. Blood 1993;82:1960-1974.
24. Ihle JN. Interleukin-3 and hematopoiesis. Chem Immunol 1992;51:65-106.
25. Metcalf D. Hematopoietic regulators: redundancy or subtlety. Blood 1993;82:3515-3523.
26. Kinashi T, Inaba K, Tsubata T, Tashiro K, Palacios R, Honjo T. Differentiation of an interleukin 3-dependent precursor B-cell clone into immunoglobulin-producing cells in vitro. Proc Natl Acad Sci USA 1988;85:4473-4477.
27. Suzuki H, Katayama N, Ikuta Y, Mukai K, Fujieda A, Mitani H, Araki H, Miyashita H, Hoshino N, Nishikawa H, Nishii K, Minami N, Shiku H. Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. Am J Hematol 2004;75:179-189.
28. Itakura A, Miura Y, Hikasa Y, Kiso Y, Matsuda H. Interleukin-3 and stem cell factor modulate cell cycle regulatory factors in mast cells: negative regulation of p27Kip1 in proliferation of mast cells induced by interleukin-3 but not stem cell factor. Exp Hematol 2001;29:803-811.
29. Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004;59:793-805.
30. Yamada M, Suzu S, Tanaka-Douzono M, Wakimoto N, Hatake K, Hayasawa H, Motoyoshi K. Effect of cytokines on the proliferation/differentiation of stroma-initiating cells. J Cell Physiol 2000;184:351-355.
31. Kitamura T, Sato N, Arai K, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell 1991;66:1165-1174.
32. Guthridge MA, Stomski FC, Thomas D. Mechanism of activation of the GM-CSF-IL-3, and IL-5 family of receptors. Stem Cells 1998;16:301-313.
33. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999;13:1109-1166.
34. Blaikie P, Immanuel D, Wu J, Li N, Yajnik V, Margolis B. A region in Shc distinct from the SH2 domain can bind tyrosine-phosphorylated growth factor receptors. J Biol Chem 1994;269:32031-32034.
35. Berra E, Diaz-Meco MT, Lozano J, Frutos S, Municio MM, Sanchez P, Sanz L, Moscat J. Evidence for a role of MEK and MAPK during signal transduction by protein kinase C zeta. EMBO J 1995;14:6157-6163.
36. Kinoshita T, Shirouzu M, Kamiya A, Hashimoto K, Yokoyama S, Miyajima A. Raf/MAPK and rapamycin-sensitive pathways mediate the anti-apoptotic function of p21Ras in IL-3-dependent hematopoietic cells. Oncogene 1997;15:619-627.
37. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 1996;87:619-628.
38. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 1999;401:86-90.
39. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999;401:82-85.
40. Lee HH, Dadgostar H, Cheng Q, Shu. J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999;96:9136-9141.
41. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18:6910-6924.
42. Grossmann M, O'Reilly LA, Gugasyan R, Strasser A, Adams JM, Gerondakis S. The anti-apoptotic activities of Rel and RelA required during B-cell maturation involve the regulation of Bcl-2 expression. EMBO J 2000;19:6351-6360.
43. Guthridge MA, Barry EF, Felquer FA, McClure BJ, Stomski FC, Ramshaw H, Lopez AF. The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Blood 2004;103:820-827.
44. Wang JM, Lai MZ, Yang-Yen HF. Interleukin-3 stimulation of mcl-1 gene transcription involves activation of the PU.1 transcription factor through a p38 mitogen-activated protein kinase-dependent pathway. Mol Cell Biol 2003;23:1896-1909.
45. Kieslinger M, Woldman I, Moriggl R, Hofmann J, Marine JC, Ihle JN, Beug H, Decker T. Anti-apoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev 2000;14:232-244.
46. Baskiewicz-Masiuk M, Machalinski B. The role of the STAT5 proteins in the proliferation and apoptosis of the CML and AML cells. Eur J Haematol 2004;72:420-429.
47. Bosshart H. Interleukin-3 receptors in Hodgkin's disease. Am J Pathol 2003;162:355-356.
48. Thomas RK, Re D, WolfJ, Diehl V. Hodgkin's lymphoma - molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004;5:11-18.
49. Marafioti T, Pozzobon M, Hansmann ML, Delsol G, Pileri SA, Mason DY. Expression of intracellular signaling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004;103:188-193.
50. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, Wirth T, Demel G, Falini B. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001;97:496-501.
51. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998;16:471-493.
52. Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999;36:233-241.
53. Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, Ricciardi-Castagnoli P, Rosen CA, Carter KC. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999;94:411-416.
54. Schwering I, Brauninger A, Klein U, Jungnickel B, Tinguely M, Diehl V, Hansmann ML, Dalla-Favera R, Rajewsky K, Kuppers R. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003;101:1505-1512.
55. Kuppers R, Klein U, Schwering I, Distler V, Brauninger A, Cattoretti G, Tu Y, Stolovitzky GA, Califano A, Hansmann ML, Dalla-Favera R. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J Clin Invest 2003;111:529-537.
56. Carbone A, Gloghini A, Gaidano G, Franceschi S, Capello D, Drexler HG, Falini B, Dalla-Favera R. Expression status of BCL-6 and syndecan-1 identifies distinct histogenic subtypes of Hodgkin's disease. Blood 1998;92:2220-2228.
57. Carbone A, Gloghini A, Gattei V, Degan M, Improta S, Aldinucci D, Canzonieri V, Perin T, Volpe R, Gaidano G, Zagonel V, Pinto A. Reed-Sternberg cells of classical Hodgkin's disease react with the plasma cell-specific monoclonal antibody B-B4 and express human syndecan-1. Blood 1997;89:3787-3794.
58. Sato N, Caux C, Kitamura I, Watanabe Y, Arai K, Banchereau J, Miyajima A. Expression and factor-dependent modulation of the interleukin-3 receptor subunits on human hematopoietic cells. Blood 1993;82:752-761.
59. Macardle PJ, Chen Z, Shih C-Y, Huang CM, Weedon H, Sun Q, Lopez AF, Zola H. Characterization of human leucocytes bearing the IL-3 receptor. Cell Immunol 1996;168:59-68.
60. Wörmann B, Gesner TG, Mufson RA, LeBien TW. Proliferative effect of interleukin-3 on normal and leukemic human B-cell precursors. Leukemia 1989;3:399-404.
61. Park L, Waldron PE, Friend D, Sassenfeld HM, Price V, Anderson D, Cosman D, Andrews RG, Bernstein ID, Urdal DL. Interleukin-3, GM-CSF and G-CSF receptor expression on cell lines and primary leukemia cells: receptor heterogeneity and relationship to growth factor responsiveness. Blood 1989;74:56-65.
62. Uckun FM, Gesner TG, Song CW, Mayers DE, Mufson A. Leukemic B-cell precursors express functional receptors for human interleukin-3. Blood 1989;73:533-542.
63. Nishii K, Katayama N, Miwa H, Shikami M, Masuya M, Shiku H, Kita K. Survival of human leukemic B-cell precursors is supported by stromal cells and cytokines: association with the expression of bcl-2 protein. Br J Haematol 1999;105:701-710.
64. Clayberger C, Luna-Fineman S, Lee JE, Pillai A, Campbell M, Levy R, Krensky AM. Interleukin 3 is a growth factor for human follicular B cell lymphoma. J Exp Med 1992;175:371-376.
65. Younes A, Drach J, Katz R, Jendiroba D, Sabourian MH, Sarris AH, Swan F Jr, Hill D, Cabanillas F, Ford R. Growth inhibition of follicular small-cleaved-cell lymphoma cells in short-term culture by interleukin-3. Ann Oncol 1994;5:265-268.
66. Trentin L, Zambello R, Agostini C, Enthammer C, Cerruti A, Adami F, Zamboni S, Semenzato G. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 1994;84:4249-4256.
67. Bergui L, Schena M, Gaidano G, Riva M, Calligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote die proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 1989;170:613-618.
68. Lee JW, Chung HY, Ehrlich LA, Jelinek DF, Callander NS, Roodman GD, Choi SJ. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004;103:2308-2315.
69. Sahin U, Neumann F, Tureci O, Schmits R, Perez F, Pfreundschuh M. Hodgkin and Reed-Sternberg cell-associated autoantigen CLIP-170/restin is a marker for dendritic cells and is involved in the trafficking of macropinosomes to the cytoskeleton, supporting a function-based concept of Hodgkin and Reed-Sternberg cells. Blood 2002;100:4139-4145.
70. Delabie J, Chan WC, Weisenburger DD, De Wolfe-Peeters C. The antigen-presenting-cell function of Reed-Sternberg cells. Leuk Lymphoma 1995;18:35-40.
71. Poppema S, Potters M, Emmens R, Visser L, van den Berg A. Immune reactions in classical Hodgkin's lymphoma. Semin Hematol 1999;36:253-259.
72. Pinkus GS, Pinkus GL, Langhoff E, Mtasumura F, Yamashiro S, Mosialos G, Said JW. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation. Am J Pathol 1997;150:543-562.
73. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1695.
74. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
75. Kinoshita T, Yokota T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signaling through the IL-3/GM-CSF receptors. EMBO J 1995;14:266-275.
76. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992;80:1750-1757.
77. Hsu SM, Hsu PL. Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells. Comparison with effects of phorbol ester and retinoic acid. Am J Pathol 1990;136:181-189.
78. Fischer M, Bijman M, Molin D, Cormont F, Uyttenhove C, van Snick J, Sundstrom C, Enblad G, Nilsson G. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkin's lymphoma. Leukemia 2003;17:2513-2516.
79. Carbone A, Gloghini A, Gattei V, Aldinucci D, Degan M, De Paoli P, Zagonel V, Pinto A. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell line. Blood 1995;85:780-789.
80. Pinto A, Gloghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A. Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphomas. Blood 1994;83:785-792.
81. Aldinucci D, Poletto D, Nanni P, Degan M, Gloghini A, Di Francia R, Russo S, Carbone A, Pinto A, Gattei V. Hodgkin and Reed-Sternberg cells express functional c-kit receptors and interact with primary fibroblasts from Hodgkin's disease-involved lymph nodes through soluble and membrane-bound stem cell factor. Br J Haematol 2002;118:1055-1064.
82. Aldinucci D, Gattei V. The role of interleukin-3 and stem cell factor in classical Hodgkin disease. Blood 2003;101:376-377.
83. Rassidakis GZ, Georgakis GV, Oyarzo M, Younes A, Medeiros LJ. Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis. Mod Pathol 2004;17:946-953.
84. Rassidakis GZ, Georgakis GV, Younes A, Medeiros LJ. c-kit is not expressed in Hodgkin disease and anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma. Blood 2003;102:4619-4620.
85. Brown RE, Nazmi RK. The Reed-Steinberg cell: molecular characterization by proteomic analysis with therapeutic implications. Ann Clin Lab Sci 2002;32:339-351.
86. Re D, Wickenhauser C, Ahmadi T, Buchdunger E, Kochanek M, Diehl V, Wolf J. Preclinical evaluation of the antiproliferative potential of STI571 in Hodgkin's disease. Br J Cancer 2002;86:1333-1335.
87. Yu J, Zhang L. Apoptosis in human cancer cells. Curr Opin Oncol 2004;16:19-24.
88. Re D, Hofmann A, Wolfe J, Diehl V, Staratschek-Jox A. Cultivated H-RS cells are resistant to CD95L-mediated apoptosis despite expression of wild-type CD95. Exp Hematol 2000;28:31-35.
89. Metkar SS, Naresh KN, Redkar AA, Nadkarni JJ. CD40-ligation-mediated protection from apoptosis of a Fas-sensitive Hodgkin's-disease-derived cell line. Cancer Immunol Immunother 1998;47:104-112.
90. Merz H, Fliedner A, Orscheschek K, Binder Th, Sebald W, Muller-Hermelink HK, Feller AC. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Am J Pathol 1991;139:1173-1180.
91. Trümper LH, Brady G, Bagg A, Gray D, Locke SL, Griesser H, Wagman R, Braziel R, Gascoyne RD, Vicini S. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 1993;81:3097-3115.
92. Gregory B, Kirchem A, Phipps S, Gevaert P, Pridgeon C, Rankin SM, Robinson DS. Differential regulation of human eosinophil IL-3, IL-5, and GM-CSF receptor alpha-chain expression by cytokines: IL-3, IL-5, and GM-CSF down-regulate IL-5 receptor alpha expression with loss of IL-5 responsiveness, but up-regulate IL-3 receptor alpha expression. J Immunol 2003;170:5359-5366.
93. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
94. Cohen S, Mosmann T. Cytokine profiles. Immunol Today 2000;21:199-200.
95. Aoki I, Tanaka S, Ishii N, Minami M, Klinman DM. Contribution of interleukin-3 to antigen-induced Th2 cytokine production. Eur J Immunol 1996;26:1388-1393.
96. Dan Y, Katakura DY, Ametani A, Kaminogawa S, Asano Y. IL-3 augments TCR-mediated responses of type 2 CD4 T cells. J Immunol 1996;156:27-34.
97. Teruya-Feldstein J, Tosato G, Jaffe ES. The role of chemokines in Hodgkin's disease. Leuk Lymphoma 2000;38:363-371.
98. Nimer S, Zhang J, Avraham H, Miyazaki Y. Transcriptional regulation of interleukin-3 expression in megakaryocytes. Blood 1996;88:66-74.
99. Guba SC, Stella G, Turka LA, June CH, Thompson CB, Emerson SG. Regulation of interleukin 3 gene induction in normal human T cells. J Clin Invest 1989;84:1701-1706.
100. Park J-H, Kaushansky K, Levitt L. Transcriptional regulation of interleukin 3 (IL3) in primary human T lymphocytes. Role of AP-1 and octamer-binding proteins in control of IL3 gene expression. J Biol Chem 1993;268:6299-6308.
101. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992;357:695-697.
102. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-456.
103. Gebhardt T, Sellge G, Lorentz A, Raab R, Manns MP, Bischoff SC. Cultured human intestinal mast cells express functional IL-3 receptors and respond to IL-3 by enhancing growth and IgE receptor-dependent mediator release. Eur J Immunol 2002;32:2308-2316.
104. Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004;24:271-281.
105. Pinto A, Aldinucci D, Gloghini A, Zagonel V, De Iuliis A, Degan M, Improta S, Todesco M, Perin V, Sacco C, Gattei V, Gruss H-J, Carbone A. The role of eosinophils in the pathobiology of Hodgkin's disease. Ann Oncol 1997;8:89-96.